stoxline Quote Chart Rank Option Currency Glossary
  
Amarin Corporation plc (AMRN)
1.19  0.01 (0.85%)    02-23 16:00
Open: 1.18
High: 1.2
Volume: 748,623
  
Pre. Close: 1.18
Low: 1.16
Market Cap: 486(M)
Technical analysis
2024-02-23 4:34:56 PM
Short term     
Mid term     
Targets 6-month :  1.44 1-year :  1.6
Resists First :  1.23 Second :  1.37
Pivot price 1.19
Supports First :  1.01 Second :  0.84
MAs MA(5) :  1.18 MA(20) :  1.2
MA(100) :  0.91 MA(250) :  1.12
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  44.8 D(3) :  37.9
RSI RSI(14): 53
52-week High :  2.17 Low :  0.64
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AMRN ] has closed above bottom band by 45.2%. Bollinger Bands are 54.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.2 - 1.21 1.21 - 1.21
Low: 1.15 - 1.15 1.15 - 1.16
Close: 1.18 - 1.19 1.19 - 1.2
Company Description

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Headline News

Thu, 22 Feb 2024
Amarin (AMRN) Scheduled to Post Earnings on Thursday - MarketBeat

Thu, 08 Feb 2024
Premarket Mover: Amarin Corporation plc (AMRN) Up 6.67% - InvestorsObserver

Wed, 31 Jan 2024
Amarin Corporation plc (AMRN) Down 2.42% in Premarket Trading - InvestorsObserver

Wed, 10 Jan 2024
Amarin shares surge on higher-than-expected preliminary Q4 results (NASDAQ:AMRN) - Seeking Alpha

Wed, 03 Jan 2024
Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified - Simply Wall St

Mon, 04 Dec 2023
Sarissa Capital Believes Amarin (AMRN) Stock Is Meaningfully Undervalued, Increases Its Ownership - StreetInsider.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 408 (M)
Shares Float 381 (M)
Held by Insiders 0.5 (%)
Held by Institutions 23.8 (%)
Shares Short 14,400 (K)
Shares Short P.Month 13,620 (K)
Stock Financials
EPS -0.12
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.35
Profit Margin -16.3 %
Operating Margin -12.3 %
Return on Assets (ttm) -1.7 %
Return on Equity (ttm) -9.2 %
Qtrly Rev. Growth -26.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.78
EBITDA (p.s.) -0.05
Qtrly Earnings Growth 0 %
Operating Cash Flow 9 (M)
Levered Free Cash Flow -29 (M)
Stock Valuations
PE Ratio -9.92
PEG Ratio -0.3
Price to Book value 0.88
Price to Sales 1.5
Price to Cash Flow 53.5
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android